共 59 条
- [11] Shi L.M., Fan Y., Myers T.G., O'Connor P.M., Paull K.D., Friend S.H., Et al., Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues, J. Chem. Inf. Comput. Sci, 38, pp. 189-199, (1998)
- [12] Wu L., Et al., Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening, Cancer Res, 52, pp. 3029-3034, (1992)
- [13] Lee J.-S., Et al., Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen, Mol. Phormacol, 46, pp. 627-638, (1994)
- [14] Alvarez M., Et al., Generation of a drug resistance profile by quantitation of MDR-I/P-glycoprotein expression in the cell lines of the NCI anticancer drug screen, J. Clin. Invest, 95, pp. 2205-2214, (1995)
- [15] Bates S.E., Et al., Molecular targets in the National Cancer Institute drug screen, J. Cancer Res. Clin. Oncol, 121, pp. 495-500, (1995)
- [16] Izquierdo M.A., Et al., Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines, Int. J. Cancer, 65, pp. 230-237, (1996)
- [17] Koo H.-M., Et al., Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase 11 inhibitors in tumor cell lines harboring activated ras oncogenes, J. Natl. Cancer Inst, 56, pp. 5211-5216, (1996)
- [18] O'Connor P.M., Et al., Characterization of the p53-tumor suppressor pathway in cells of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res, 57, pp. 4285-4300, (1997)
- [19] Freije J.M., Et al., Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines, Nat. Med, 3, pp. 395-401, (1997)
- [20] Wosikowski K., Et al., Identification of epidermal growth factor receptor and c-erbB2 pathway inhibitors by correlation with gene expression patterns, J. Natl. Cancer Inst, 89, pp. 1505-1513, (1997)